news Nanobody could be used as antiviral treatment against COVID-19 4 September 2020 | By Victoria Rees (Drug Target Review) Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
news UK government to invest £8.4 million into COVID-19 immunology research 1 September 2020 | By Victoria Rees (Drug Target Review) The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
news Novel protection pathway makes cells resistant to Ebola and coronavirus infection, report scientists 28 August 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
news Inhibiting growth factor signalling prevents SARS-CoV-2 replication, report researchers 26 August 2020 | By Hannah Balfour (Drug Target Review) Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
news Tracking SARS-CoV-2 evolution: notable mutations and potential targets 26 August 2020 | By Hannah Balfour (Drug Target Review) Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
news Two biomarkers of COVID-19 disease survival identified by researchers 25 August 2020 | By Victoria Rees (Drug Target Review) Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
news Researchers identify protein that may help SARS-CoV-2 spread through cells 14 August 2020 | By Victoria Rees (Drug Target Review) Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
news Machine learning reveals potential COVID-19 therapeutic compounds 13 August 2020 | By Victoria Rees (Drug Target Review) A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
news Potential COVID-19 treatment and vaccine combination shows success in cells 12 August 2020 | By Victoria Rees (Drug Target Review) A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
news Five biomarkers revealed as indicators of COVID-19 patient survival 10 August 2020 | By Victoria Rees (Drug Target Review) Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
news Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells 7 August 2020 | By Victoria Rees (Drug Target Review) Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
news Decoy ACE2 receptors show promise as COVID-19 treatment in cell cultures 5 August 2020 | By Victoria Rees (Drug Target Review) A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
news Near-identical protein on SARS and COVID-19 could be targeted by FDA-approved drugs 3 August 2020 | By Victoria Rees (Drug Target Review) According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
news Majority of T-cell targets not on COVID-19 Spike protein, study finds 31 July 2020 | By Victoria Rees (Drug Target Review) Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
news Functioning lung cell assay for modelling COVID-19 infections developed 31 July 2020 | By Victoria Rees (Drug Target Review) A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
